These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8819183)

  • 1. Airway effects of salmeterol in healthy individuals.
    Bergendal A; Johansson A; Bake B; Lötvall J; Skoogh BE; Löfdahl CG
    Pulm Pharmacol; 1995 Dec; 8(6):283-8. PubMed ID: 8819183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo.
    Ball DI; Brittain RT; Coleman RA; Denyer LH; Jack D; Johnson M; Lunts LH; Nials AT; Sheldrick KE; Skidmore IF
    Br J Pharmacol; 1991 Nov; 104(3):665-71. PubMed ID: 1686740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol.
    Grove A; Lipworth BJ
    Thorax; 1996 Jan; 51(1):54-8. PubMed ID: 8658370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the effect of salmeterol and salbutamol in normal subjects.
    Spring J; Clague J; Ind PW
    Br J Clin Pharmacol; 1992 Feb; 33(2):139-41. PubMed ID: 1348000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects.
    Bennett JA; Tattersfield AE
    Thorax; 1997 May; 52(5):458-64. PubMed ID: 9176539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism.
    Lindén A; Bergendal A; Ullman A; Skoogh BE; Löfdahl CG
    Thorax; 1993 May; 48(5):547-53. PubMed ID: 8100652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma.
    Smyth ET; Pavord ID; Wong CS; Wisniewski AF; Williams J; Tattersfield AE
    BMJ; 1993 Feb; 306(6877):543-5. PubMed ID: 8096416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
    van der Woude HJ; Winter TH; Aalbers R
    Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The duration of bronchodilation of salmeterol and salbutamol as measured by specific airway conductance in healthy subjects.
    Pullerits T; Ventresca P; Lötvall J
    Pulm Pharmacol Ther; 2011 Feb; 24(1):55-8. PubMed ID: 21035560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of cyclic AMP accumulation and relaxant actions of salmeterol and salbutamol in bovine tracheal smooth muscle.
    Ellis KE; Mistry R; Boyle JP; Challiss RA
    Br J Pharmacol; 1995 Nov; 116(5):2510-6. PubMed ID: 8581292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo effect of albuterol on methacholine-contracted bronchi in conjunction with salmeterol and formoterol.
    Aziz I; Lipworth BJ
    J Allergy Clin Immunol; 1999 May; 103(5 Pt 1):816-22. PubMed ID: 10329815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients.
    Ullman A; Svedmyr N
    Thorax; 1988 Sep; 43(9):674-8. PubMed ID: 2904183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-response study with high-dose inhaled salmeterol in healthy subjects.
    Maconochie JG; Forster JK
    Br J Clin Pharmacol; 1992 Mar; 33(3):342-5. PubMed ID: 1349491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease.
    Matera MG; Cazzola M; Vinciguerra A; Di Perna F; Calderaro F; Caputi M; Rossi F
    Pulm Pharmacol; 1995 Dec; 8(6):267-71. PubMed ID: 8819181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does tachyphylaxis occur to the non-pulmonary effects of salmeterol?
    Maconochie JG; Minton NA; Chilton JE; Keene ON
    Br J Clin Pharmacol; 1994 Feb; 37(2):199-204. PubMed ID: 7910472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigations into factors determining the duration of action of the beta 2-adrenoceptor agonist, salmeterol.
    Nials AT; Sumner MJ; Johnson M; Coleman RA
    Br J Pharmacol; 1993 Feb; 108(2):507-15. PubMed ID: 8095419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The contribution of the swallowed fraction of an inhaled dose of salmeterol to it systemic effects.
    Bennett JA; Harrison TW; Tattersfield AE
    Eur Respir J; 1999 Feb; 13(2):445-8. PubMed ID: 10065696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the profiles of agonists as stimulants of the beta 3-adrenoceptor in vitro with their gastroprotective effects in the conscious rat.
    Bahl AK; Clayton NM; Coates J; Martin DP; Oakley IG; Strong P; Trevethick MA
    Br J Pharmacol; 1996 Feb; 117(3):580-586. PubMed ID: 8821552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of long-acting and short-acting beta-agonists on methacholine dose-response curves in asthmatics.
    Wong AG; O'Shaughnessy AD; Walker CM; Sears MR
    Eur Respir J; 1997 Feb; 10(2):330-6. PubMed ID: 9042628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-adrenoceptor subtypes and the opening of plasmalemmal K(+)-channels in trachealis muscle: electrophysiological and mechanical studies in guinea-pig tissue.
    Cook SJ; Small RC; Berry JL; Chiu P; Downing SJ; Foster RW
    Br J Pharmacol; 1993 Aug; 109(4):1140-8. PubMed ID: 8104643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.